Identification of non-classical hCA XII inhibitors using combination of computational approaches for drug design and...

Area of Science:

• Biochemistry
• Pharmacology
• Computational Chemistry

Background:

• Human carbonic anhydrase XII (hCA XII) is a significant therapeutic target and biomarker in various cancers.
• hCA XII regulates pH, influencing cancer cell proliferation, invasion, growth, and metastasis.
• Traditional hCA inhibitors, often sulfonamide-based, lack selectivity and can cause sulfa allergies.

Purpose of the Study:

• To identify novel, non-classical inhibitors of hCA XII.
• To address the limitations of existing sulfonamide-based hCA inhibitors.
• To discover alternative chemical scaffolds for hCA XII-targeted cancer therapies.

Main Methods:

• Utilized a comprehensive computational drug design approach.
• Generated and validated structure- and ligand-based pharmacophore models.
• Employed molecular docking, MMGBSA re-scoring, and molecular dynamics simulations.

Main Results:

• Identified several compounds with novel chemical scaffolds as potential hCA XII inhibitors.
• A coumarin derivative showed particular interest as a non-classical inhibitor.
• The study validated the computational methods for discovering new drug candidates.

Conclusions:

• Novel non-classical inhibitors for hCA XII were successfully identified using computational methods.
• The identified compounds, including a coumarin derivative, represent promising alternatives to traditional inhibitors.
• This research paves the way for developing more selective and safer hCA XII-targeted cancer therapies.